NADPH oxidase-mediated platelet isoprostane over-production in cirrhotic patients: implication for platelet activation

被引:38
作者
Basili, Stefania [1 ]
Raparelli, Valeria [1 ]
Riggio, Oliviero [2 ]
Merli, Manuela [2 ]
Carnevale, Roberto [1 ]
Angelico, Francesco [1 ]
Tellan, Guglielmo [3 ]
Pignatelli, Pasquale [1 ]
Violi, Francesco [1 ]
机构
[1] Univ Rome, Div Clin Med 1, Dipartimento Med Interna & Specialita Med, I-00161 Rome, Italy
[2] Univ Rome, Dipartimento Med Clin Med Crit & Terapia Dolore, I-00161 Rome, Italy
[3] Univ Rome, Dipartimento Sci Anestesiol Med Crit & Terapia Do, I-00161 Rome, Italy
关键词
cirrhosis; isoprostanes; platelet activation; BLEEDING-TIME; IN-VIVO; LIPID-PEROXIDATION; OXIDATIVE STRESS; LIVER; F-2-ISOPROSTANES; RECEPTORS; MARKERS; PLASMA; CD40;
D O I
10.1111/j.1478-3231.2011.02617.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: In patients with cirrhosis conflicting findings, inherent to platelet function and its clinical implication, are still matters of discussion. Cirrhosis is characterized by enhanced production of isoprostanes, index of oxidative stress in vivo, that is known to stem from nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 2 (NOX2)-generating oxidative stress and elicit platelet activation. Aim: To analyse the relationship between oxidative stress and platelet activation in cirrhosis. Methods: A cross-sectional study including 51 cirrhotic patients and sex-and age-matched control patients has been designed. Soluble NOX2-derived peptide (sNOX2-dp), a direct marker of NADPH oxidase activation, isoprostanes urinary excretion, platelet isoprostanes and two markers of in vivo platelet activation, i.e. soluble CD40 Ligand (sCD40L) and soluble P-selectin (sPs), were measured. Results: Compared with controls, cirrhotic patients had higher levels of sPs (P = 0.034), sCD40L (P < 0.0001), sNOX2-dp (P = 0.0016), urinary excretion of isoprostanes (P < 0.0001) and arachidonic acid-induced platelet isoprostane formation (P < 0.0001). A significant correlation between sNOX2-dp and platelet (R-s = 0.39, P = 0.0051) and urinary (R-s = 0.67, P < 0.0001) isoprostanes was detected; also, sNOX2-dp and isoprostanes significantly correlated with sPs and sCD40L. A stepwise regression analysis revealed that sNOX2-dp was independently related to sCD40L plasma levels. Conclusions: This study provides evidence that in cirrhosis, platelet isoprostanes are over-produced and could be implicated in platelet activation.
引用
收藏
页码:1533 / 1540
页数:8
相关论文
共 39 条
[1]   Thrombocytopenia associated with chronic liver disease [J].
Afdhal, Nezam ;
McHutchison, John ;
Brown, Robert ;
Jacobson, Ira ;
Manns, Michael ;
Poordad, Fred ;
Weksler, Babette ;
Esteban, Rafael .
JOURNAL OF HEPATOLOGY, 2008, 48 (06) :1000-1007
[2]   Parenchymal Extinction: Coagulation and Hepatic Fibrogenesis [J].
Anstee, Quentin M. ;
Wright, Mark ;
Goldin, Robert ;
Thursz, Mark R. .
CLINICS IN LIVER DISEASE, 2009, 13 (01) :117-+
[3]   BLEEDING-TIME IN PATIENTS WITH HEPATIC CIRRHOSIS [J].
BLAKE, JC ;
SPRENGERS, D ;
GRECH, P ;
MCCORMICK, PA ;
MCINTYRE, N ;
BURROUGHS, AK .
BRITISH MEDICAL JOURNAL, 1990, 301 (6742) :12-15
[4]   11-DEHYDROTHROMBOXANE-B2 - A QUANTITATIVE INDEX OF THROMBOXANE-A2 FORMATION IN THE HUMAN CIRCULATION [J].
CATELLA, F ;
HEALY, D ;
LAWSON, JA ;
FITZGERALD, GA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1986, 83 (16) :5861-5865
[5]   F2-isoprostanes are not just markers of oxidative stresse [J].
Comporti, Mario ;
Signorini, Cinzia ;
Arezzini, Beatrice ;
Vecchio, Daniela ;
Monaco, Barbara ;
Gardi, Concetta .
FREE RADICAL BIOLOGY AND MEDICINE, 2008, 44 (03) :247-256
[6]  
Comporti M, 2009, HISTOL HISTOPATHOL, V24, P893, DOI 10.14670/HH-24.893
[7]  
Davì G, 1998, THROMB HAEMOSTASIS, V79, P747
[8]  
DESAI K, 1989, LANCET, V1, P693
[9]   Soluble P-selectin as a marker of in vivo platelet activation [J].
Ferroni, Patrizia ;
Martini, Francesca ;
Riondino, Silvia ;
La Farina, Francesca ;
Magnapera, Agesilao ;
Ciatti, Filippo ;
Guadagni, Fiorella .
CLINICA CHIMICA ACTA, 2009, 399 (1-2) :88-91
[10]   Effectiveness of antiplatelet drugs against experimental non-alcoholic fatty liver disease [J].
Fujita, K. ;
Nozaki, Y. ;
Wada, K. ;
Yoneda, M. ;
Endo, H. ;
Takahashi, H. ;
Iwasaki, T. ;
Inamori, M. ;
Abe, Y. ;
Kobayashi, N. ;
Kirikoshi, H. ;
Kubota, K. ;
Saito, S. ;
Nagashima, Y. ;
Nakajima, A. .
GUT, 2008, 57 (11) :1583-1591